June 16, 2025
TOPLINE: Asciminib, a first-in-class BCR–ABL1 TKI, showed high molecular response rates and was well tolerated in the first prospective trial of its kind evaluating the drug […]
June 16, 2025
MILAN — An unexpected highlight here at this year’s European Hematology Association (EHA) Congress came from beyond planet Earth. In a packed session titled Space Hematology, […]
June 16, 2025
TOPLINE: A novel, single-use on-body injector (OBI) for isatuximab in multiple myeloma is noninferior to the standard intravenous (IV) formulation in efficacy and pharmacokinetics and has […]
June 16, 2025
TOPLINE: Combination therapy with avelumab plus axitinib demonstrated a clinical benefit in patients with advanced gastrointestinal stromal tumour (GIST), achieving a 69.6% disease control rate and […]
June 16, 2025
TOPLINE: The programmed cell death protein 1 (PD-1) inhibitor drug sintilimab in combination with the standard chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) shows significant […]
June 16, 2025
A new ultrasound-based treatment that destroys liver cancer tumours without surgery or radiation will be offered to NHS patients this summer in a European first. The […]
June 16, 2025
Mrs G.O. is an 80-year-old retired teacher who was widowed a decade ago. With no close relatives, she lives alone, accompanied by only two cats and […]
June 15, 2025
MILAN — Combining polatuzumab vedotin (Pola) with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improves survival outcomes in patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma […]
June 14, 2025
MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly “minimal”) residual disease (MRD). Once confined […]